The Life Sciences team advised Atrandi Biosciences, a Vilnius, Lithuania based biotech, on a $25 million Series A financing round led by Lux Capital, with participation from Vsquared Ventures, Practica Capital, Metaplanet, and GRIDS Capital. The funding will go towards the company's expansion into the U.S. market, including opening an office in Boston later this year, growth of its semi-permeable capsule technology, and new product development.
Atrandi Biosciences is transforming single-cell analysis with its patented Semi-Permeable Capsule (SPC) technology, enabling scalable, true single-cell multiomics. By simplifying complex workflows, Atrandi accelerates discoveries in cellular heterogeneity, clonal evolution, microbiome diversity, microbial ecology, and more.
The Goodwin team included Mark Macenka (Technology), Mayan Katz, Amine Assouad, and Aiste Zalepuga (Life Sciences Corporate), Sarah Bock (Executive Compensation & Benefits), Alex Apostolopoulos (Tax), Richard Matheny and Gozde Guckaya (Global Trade), Susan Abbott and Tyler Allain (Trusts and Estates), Natascha George (ERISA), Christina Lewis (Labor & Employment), Kathleen Kean (Licensing), and Maggie Wong (Opinions), with invaluable assistance from Carolyn Nguyen, Kaitlyn Buffaloe, Keith Janowitz, and Anikó Bouley.
For more information, please read the press release and announcement in Global Newswire, as well as coverage in Endpoints News.